cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC). Conference Paper uri icon

authors

  • Gan, Hui Kong
  • Lickliter, Jason
  • Millward, Michael
  • Gu, Yi
  • Weiguo, SU
  • Qi, Chuan
  • MU, Hua
  • Frigault, Melanie
  • Morgan, Shethah
  • Gardner, Humphrey Athelstan
  • Albiges, Laurence
  • Pal, Sumanta Kumar
  • Burris, Howard A
  • Choueiri, Toni K

publication date

  • March 1, 2015